The proteome-level data obtained by us provide a stepwise clinical procedure in YARS-positive breast cancer patients, which involves an initial screening test for YARS, followed by treatment of YARS-positive breast cancer patients with SM and BCL2 inhibitors. The gene discussed is BCL2; the disease is breast carcinoma.